The clinical implementation of gene therapy requires large-scale production of viral vector stocks (VS) derived from packaging cell lines. Upon scaling-up, maintenance of high viral titers and filtration of the VS become significantly challenging. Thus, production schemes amenable to straightforward validation must be developed. To this end, we have established a semi-closed process to manufacture batches of 7 l or more of clinical-grade oncoretroviral VS using 10-tray Cell Factories. Using a peristaltic pump, the VS are collected on 3 consecutive days, filtered, pooled and stored frozen. To ensure the absence of viable vectorproducing cells (VPCs) from each VS unit-dose, we undertook an orthogonal log-removal validation study to demonstrate the ability of both the filtration system to remove viable cells and the VS freezing process to inactivate them. We demonstrate a total VPC-reduction of 11.6 log, thus insuring the absence of contaminating VPCs in transduced clinical samples. We also show that this production process generates stable VS that can be stored at À801C for more than 3 years. Importantly, this relatively simple and affordable process can be customized to generating large volume of VS for small animal or nonhuman primate studies. This methodology is not limited to the generation of cell-free clinical oncoretroviral VS, and can be applied to other types of vectors produced in packaging cell lines, such as lentiviral vectors. Gene Therapy (2006) 13, 95-100.
Regulatory requirements stipulate that the production of any agents intended for use in human clinical trials must be performed under current Good Manufacturing Practices (cGMP). 1 Retroviral vector stocks (VS) to be used for the generation of genetically modified cellular therapeutics fall within these requirements. These entail the performance of all production activities in an aseptic manner and the removal of any potentially unsafe contaminants, such as viable vector-producing cells (VPCs), from the product.
Various methodologies have been investigated to scale-up oncoretroviral vector production. [2] [3] [4] [5] [6] [7] With the exception of roller bottles and Cell Factories, all other large-scale systems utilize at least some nondisposable parts that need to be reused, thus necessitating the performance of extensive cleaning and sterilization validation studies.
Therefore, we have designed a simplified, rapid system for large-scale cell culture in multiple 10-tray Cell Factories, which is capable of generating 7 l or more of VS. To remove residual cells from the harvested VS, we have adapted and modified the step-filtration system originally developed by Reeves and Cornetta 8 as this system has been demonstrated to yield superior infectious viral titers, compared to standard membrane filters. By incorporating the use of a peristaltic pump, we have reduced the time needed to filter the clinical VS and therefore lessen the risk of decreasing the infectious titer. In order to achieve batch sizes of 7 l or more and to reduce biosafety testing costs, the filtered supernatant harvests collected on 3 consecutive days are eventually pooled, aliquoted into 250 ml unit-doses in sterile freezing bags and stored at À801C.
As the filtration system utilizes depth filters, breakthrough of viable cells remains a possibility. To address this issue, we undertook an orthogonal log-removal validation (LRV) study to individually assess the ability of both the filtration system to remove viable cells and the VS freezing process to inactivate them. We were able to demonstrate a total VPC-reduction of 11.6 log, thus insuring the absence of contaminating VPCs in transduced clinical samples. We describe here a simplified, rapid, scaleable and fully validated VS production process that is capable of generating multi-liter quantities of stable VS than can be stored more than 3 years at À801C for use in human clinical trials. This process can also be customized for the generation of large volume of VS for small animal or non-human primate studies as well as for the production of other vectors such as lentiviral VS.
The initial aim of this study was to successfully scaleup the production of clinical-grade VS, derived from the PG13 packaging cell line, 9 in a semiclosed system. This was accomplished through the use of 10-tray Cell Factories in which all fluid transfer is performed by peristaltic pump using sterile IV tubing sets approved for clinical use, with the assistance of a sterile connecting device (SCD). In this way, the only open manipulations requiring use of a biosafety cabinet are those needed to gain entry to the Cell Factories and empty bioprocessing bags. Since sterile, single-use tubing sets are used, cleaning and sterilization validation is unnecessary. Further, the SCD allows for the aseptic connection of IV tubing lines outside of a sterile environment, which greatly simplifies sterile fluid-handling. In addition, since standard cell culture methodology is employed, extensive process development, equipment and controls are not required. This system's scalability is limited only by benchtop and incubator space, without the need for manipulators and sterile production suites. As illustrated in Figure 1 , using sterile two-and four-way tubing adapter sets and a peristaltic pump, we are able to easily fill and empty four Cell Factories simultaneously, in a matter of minutes. Over 3 days, we can generate three 2.6 l VS harvests, for a total yield of 7.8 l. However, any desired number of 10-tray Cell Factories could be accommodated.
To optimize the removal of residual VPCs from the harvested VS, we have incorporated the step-filtration method originally described by Reeves and Cornetta 8 into our semiclosed fluid transfer system. Our system differs from that originally described in that VS is transferred through the filters by peristaltic pump at a high flow-rate (250 ml/min) rather than by gravity flow (approximately 40 ml/min). This allows for more rapid processing of the VS, which is beneficial, as VS has been demonstrated to be less stable at ambient temperature versus 41C. 10 In principle, this system is also scalable to filtration of larger volumes by running additional filter assemblies in parallel with an appropriate increase in the flow-rate.
Following filtration of each VS harvest, pooling of the filtered harvests is again accomplished using a semiclosed system. Filling of the Final-Product Cryocyte Freezing Containers is performed using a set of constructed eight-way manifolds, which allows the filling process to be performed in a fully closed manner. This effectively eliminates the possibility of external contamination and abrogates the need for extensive personnel and environmental monitoring during this critical process.
To test how the modified filtration system functions in our hands as compared to the original, we utilized a retroviral vector that we developed in our laboratory 11 for the transduction of donor lymphocytes in preparation for a phase I clinical trial. 12 This bicistronic vector SFG-NIT was previously described 11, 13 and is produced using the PG13 packaging cell line. 9 A representative example of recovery of infectivity following filtration of a 7 l VS is shown in Figure 2a . As shown at all tested viral VS dilutions, we observe approximately a 50% loss in infectious titer on indicator HeLa cells. This result corroborates the decrease of 49% in infectious titer described previously. 8 However, there is little reduction in the ability of the VS to effectively transduce primary activated T-lymphocytes after stepfiltration, as shown in Figure 2b .
One of the important issues pertains to the stability of the clinical VS upon long-term storage at À801C in Figure 1 Harvesting of VS from four cell factories using a semiclosed system. PG13NIT VS is generated, under GMP, in the MSKCC Gene Transfer Facility Vector Production Suite by expansion of one Master Cell Bank vial of PG13NITclone2 cells into four 10-tray Nunclon Cell Factories (Rochester, NY, USA) at 371C, 5% CO 2 , seeded at a density of approximately 4.5 Â 10 5 ml À1 . Highglucose DMEM (Cambrex Biosciences; Walkersville, MD, USA), supplemented with 10% FBS (Hyclone; Logan, UT, USA) is used for cell expansion. When cells attain 50-70% confluency, VS is produced by replacing the medium (625 ml per Cell Factory) and incubating at 321C, 5% CO 2 for 16-24 h, at which point the VS is harvested. A measure of 2.6 l of VS from four Cell Factories is transferred simultaneously to a 5 l sterile bioprocessing bag (TC Tech; Minneapolis, MN, USA). Fluid transfer from and into the Cell Factories is performed simultaneously by construction of a fourway manifold tubing system using sterile 4-Spike to Membrane Port Adapter Sets and sterile Plasma Transfer Sets (Baxter Healthcare; Deerfield, IL, USA) using a Wheaton Omnispense peristaltic pump and sterile 6 mm IV Additive Pump Chamber Assembly sets (Wheaton; Millville, NJ, USA), at a flow-rate of 500 ml/min. All fluid transfer tubing sets are assembled as a closed system by use of the SCD (SC-201A, Terumo Medical; Somerset, NJ, USA). Three harvests on consecutive days are thus obtained, after which, end of production (EOP) VPCs are recovered. Each harvest is processed by step-filtration on the day of collection and transferred into a second sterile 5 l bioprocessing bag upon filtration as previously described 8 using a peristaltic pump (250 ml/min). The two first harvests are stored at 41C until pooling. After filtration of the third harvest, the three filtered harvests are pooled by peristaltic pump (500 ml/min) into a sterile 10 l bioprocessing bag (TC Tech), using a manifold set constructed as described above. After pooling, the Bulk VS is aliquoted into sterile 1000 ml Cryocyte Freezing Containers (R4R9959, Baxter Oncology) at 250 ml per container, simultaneously in groups of eight by peristaltic pump (250 ml/min), using an eightway manifold constructed using sterile 2-and 4-Spike to Membrane Port Adapter Sets and sterile Plasma Transfer Sets, as described above. The Final-Filling operation is performed as a fully closed system. After filling, the VS aliquots are loaded into Cryocyte Cassettes (Custom Biogenics; Shelby Township, MI, USA) and stored at À801C. The following biosafety testing is performed on each clinical-grade VS batch, as per current guidelines: Clinical retroviral vector production M Przybylowski et al cryocyte bags. We assessed the stability of two 7 l lots of VS produced in 10-tray cell factories and filtered by step-filtration (Batches A and B) at 41 and 25 months postproduction, respectively. As shown in Figure 3a , we observe 30-50% loss in infectious titer on indicator HeLa cells at all tested viral VS dilutions in both batches. We investigated this further by using various dilutions of the VS (1:3, 1:6, 1:9) to transduce T-lymphocytes. As illustrated in Figure 3b , both VS batches are able to transduce clinically relevant number of primary activated T cells upon storage for 25-41 months at À801C, without any significant decrease in transduction efficiency using dilutions of the VS up to nine-fold. This different outcome between the two cell types may be due to differential cell surface receptor saturation of GaLV envelope receptors between HeLa cells and T-lymphocytes. 14 Importantly, the ability of the VS to transduce T-lymphocytes using dilutions up to nine-fold will allow us to considerably reduce the necessary VS volume for upcoming clinical trials and therefore the cost of manufacturing and biosafety testing. The apparent higher transduction efficiency of the T-lymphocytes with VS stored for 25 months (Batch B) as compared to the initial transduction efficiency is most likely due to variation in infectivity of T cells from one donor to another.
While we demonstrated the effectiveness of this filtration process with respect to viral recovery, transduction efficiency and stability upon storage at À801C for over 3 years, its efficiency in VPC removal also needs to be established before in can be used clinically. As the filtration system utilizes a series of depth filters, breakthrough of viable cells remains a possibility. Although this issue was previously addressed 8 by performing a step-wise challenge using suspensions of increasing cell number, this does not necessarily reflect the conditions occurring during our actual batch production runs, in which a potentially high-concentration cell suspension (10 6 -10 7 ml À1 ) will immediately encounter a filter that has not previously been conditioned with a lower concentration cell suspension, especially at the considerably higher flow-rate used in our process. For these reasons, we also undertook a comprehensive validation of our process with respect to VPC clearance.
In order to develop a means of evaluating our process validation studies and allow for the detection of low numbers of VPCs in our VS product, we developed and validated a sensitive residual PG13 cell detection assay (RCDA). As shown in Table 1 The reason for failure in the second directly plated experiment is unknown. One possibility is that random sampling error could have resulted in the spiked sample containing no cells. The probability of such sampling errors is governed by the Poisson distribution:
x! where l is the mean expected number of cells sampled and; x the actual number of cells sampled.
Therefore, there is a 95% probability of sampling at least one cell when the expected number to be sampled is three. Although this value was considered acceptable during the design of the validation study, sampling error or decrease in plating efficiency of these cells at this extremely low density remain possible. In any case, the centrifuged arm was successfully validated, allowing the centrifugation-based assay to be used for the cell clearance validation studies.
To validate the efficacy of the modified step-filtration system in removing VPCs from the VS product, we performed a challenge study in which PG13 cells were expanded into a single 10-tray Cell Factory, harvested and used to spike 2.6 l cell culture medium. The spiked medium was then filtered in exactly the manner used in the clinical production protocol and the filtrate submitted for analysis, using triplicate 250 ml samples, via , VS collected before and after step filtration was diluted as indicated in Complete DMEM containing 8 mg/ml polybrene, and used to infect 5 Â 10 4 cells, in a total volume of 1.0 ml in one well of a six-well plate, for 18-24 h at 371C. Infectious titer in transduction units per ml (TU/ml) was calculated by multiplying the observed transduction efficiency by the number of cells infected and the VS dilution factor and divided by the volume of infection (in this case 1 ml). (b) For lymphocyte transduction, VS was diluted 1:3 according to our standard transduction protocol in RPMI-1640 (Invitrogen; Carlsbad, CA, USA), containing 10% FBS and 20 IU/ml IL-2 (Chiron Corp.; Everyville, CA, USA), and used to infect 2 Â 10 6 cells in a total volume of 2.0 ml in one well of a RetroNectin (Takara Bio Inc.; Shiga, Japan)-coated (15 mg/ml, 2 h) six-well plate by spinoculation (200 g, 2 h, 41C), followed by 18-24 h at 371C. In (a) and (b), transduction efficiency was assessed by FACS, using PEanti-NGFR MAb (BD Biosciences; Franklin Lakes, NJ, USA). In (b), the profile represents untransduced or transduced T-lymphocytes stained using the PE-anti-NGFR Mab. These data are representative of two (2) independent large-scale VS Production Runs.
Clinical retroviral vector production M Przybylowski et al the centrifugation-based RCDA. As shown in Table 2 , no cells were detected in any filtered sample. If only the data from the experiment with the lowest total number of spiked cells and the highest standard deviation is considered (Trial 1), the LRV may be calculated, as follows:
LRV ¼ log 10 ðnumber of spiked cellsÞ À log 10 ðLOD of the cell detection assayÞ
Since the LOD of the cell detection assay is three cells, an LRV of 8.5770.50 is obtained for reduction in VPCs achievable by the modified step-filtration procedure. This result is similar to that which was originally published using an average flow-rate of 28.6 ml/min. 8 This provides added confidence that filtration of a 2.6 l volume at an approximately 10-fold higher flow-rate (250 ml/min) does not adversely affect the efficacy of the filtration system. As cell death would be the expected outcome of storing the Final-Product VS at À801C, in the absence of cryopreservatives, this step was also investigated for cell clearance capability. A measure of 250 ml aliquots of cell culture medium were spiked, in triplicate, with known numbers of PG13 cells, transferred into Cryocyte Freezing Containers, and stored frozen for 7 days in a manner identical to VS. Each sample was then thawed and evaluated for the presence of surviving cells by the RCDA. As shown in Table 3 , viable cells were recovered in one (1) sample spiked at the highest cell number (30 000 cells). Using the formula given above, the LRV for the VS freezing process is therefore 3.0070.09. Since filtration and freezing/thawing are able to clear residual VPCs by independent mechanisms (physical removal versus direct cell damage by icecrystal formation), they are considered orthogonal processes 15 and their individual LRVs may be summed, yielding an effective LRV, for the entire vector production process, of 11.670.6. In a worst-case situation, all of the VPCs in all four Cell Factories would detach during the first VS harvest, providing a VPC burden of approximately 10 10 total cells in 2.6 l, or 9.6 Â 10 8 cells per 250 ml VS unit-dose. It would therefore be necessary to have an effective LRV of at least 9 log to ensure the absence of viable cells from the Final-Product after thawing. The demonstrated net LRV of 11.6 log for our Clinical retroviral vector production M Przybylowski et al All flasks were then incubated at 371C, 5% CO 2 . Media were changed twice weekly for a total of 14 days. Cell colonies were then fixed with methanol, stained with carbol fuchsin and visually inspected. e Directly plated cell suspensions were transferred into three T-175 flasks (83.3 ml/flask). f Centrifuged suspensions were centrifuged at 1200 g for 10 min at ambient temperature in two (sterile 250 ml centrifuge tubes (Corning Life Sciences; Acton, MA, USA) (125 ml/tube), the upper 115 ml removed by aspiration, the cells resuspended by trituration and transferred into two T-175 flasks (10 ml/flask). ). b Percent. c In each of three separate experiments, the cells were then spiked into 2.6 l Complete DMEM and processed using the step-filtration system, utilizing two different lots of Sepacell filters, via the clinical-grade VS production protocol. The filtered, spiked medium from each experiment was immediately submitted for testing by the RCDA (centrifugation method), using triplicate 250 ml samples. The filled bags were then frozen at À801C, held for 7 days, thawed in a 371C water bath and submitted for analysis using the centrifugationbased RCDA. Results are presented as the number of positive samples/N ¼ 3.
e Log-removal value (see text).
Clinical retroviral vector production M Przybylowski et al process is two log greater than this minimal requirement, thereby providing an additional 'safety factor', which is highly desirable from a regulatory standpoint.
In summary, by using 10-tray Cell Factories in conjunction with sterile two-and four-way tubing adapter sets and a peristaltic pump, we were able to develop a scalable, GMP-compliant process for the production of high-quality VS, intended for clinical applications. We are able to generate a total yield of 7.8 l by performing three VS harvests over 3 days using only four Cell Factories. Indeed, it would be feasible to generate larger volumes of VS using any desired number of 10-tray Cell Factories. We demonstrate that we can validate our process to clear VPCs from the FinalProduct by orthogonal log-removal studies. Log-removal studies are widely recognized as the method of choice in the Biotechnology industry for evaluation of viral clearance during purification of protein-drug products, 15 but is equally suited for evaluation of the level of clearance for any potentially harmful contaminant, where even low levels may be considered hazardous. We have thus expanded the application of this methodology to include VPCs used in the manufacture of retroviral gene therapy VS. In principle, this process can also be incorporated into production schemes involving any gene transfer vector secreted by attachment-dependent mammalian cells (e.g. lentiviral vectors). While this would require revalidation of the filtration system's ability to clear the specific packaging cell type, the resulting improvement in the level of infectious titer could justify its use over traditional membrane-filtration methods. This becomes especially important if further downstream purification methods are to be employed, as these also result in significant reductions in the yield of infectious particles. Indeed, the recent publication of the manufacturing methodology employed in the first lentiviral vector for clinical use 16 indicates that an overall recovery of 30% is observed. In this case, even a modest improvement in infectivity of the starting material would result in a greater absolute Final-Product yield, thereby increasing the resulting number of Product doses prepared. Furthermore, the recent introduction of new scalable technologies (e.g. single-use membrane chromatography cartridges) may allow an entire manufacturing process (product harvesting and downstream purification) to be performed in a truly sterile manner, eliminating the need for sterile-filtration of the Final Product and the final yield reduction that is entailed.
